Novel investigational therapies for atopic dermatitis

Expert Opinion on Investigational Drugs

Volumn 24, Issue 1, 2015, Pages 61-68

  Ibler, Kristina Sophie ^a   Jemec, Gregor Be ^b  

^a ROSKILDE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Antibodies; Atopic dermatitis; Drug development; Review; Small molecules; Therapy

Indexed keywords

2 ISOPROPYL 5 [2 PHENYLETHENYL] BENZENE 1,3 DIOL; ADALIMUMAB; ALEFACEPT; ANTIINFLAMMATORY AGENT; APREMILAST; APREPITANT; CHYMASE INHIBITOR; DUPILUMAB; ETANERCEPT; INFLIXIMAB; OMALIZUMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TRADIPITANT; UNCLASSIFIED DRUG; USTEKINUMAB;

ATOPIC DERMATITIS; DERMATOLOGY LIFE QUALITY INDEX; DRUG EFFICACY; DRUG SAFETY; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; MAINTENANCE THERAPY; MAST CELL DEGRANULATION; MEDICATION THERAPY MANAGEMENT; NOCICEPTION; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PILOT STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VISUAL ANALOG SCALE;

EID: 84916624424     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2015.957756     Document Type: Review

References (63)

1. Darsow U, Wollenberg A, Simon D, et al. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2010;24:317-28
2. Vinding GR, Zarchi K, Ibler KS, et al. Is adult atopic eczema more common than we think? - A population-based study in Danish adults. Acta Derm Venereol 2014;94(4):480-2
3. Heimall J, Spergel JM. Filaggrin mutations and atopy: consequences for future therapeutics. Expert Rev Clin Immunol 2012;8:189-97
4. Elias PM. Lipid abnormalities and lipid-based repair strategies in atopic dermatitis. Biochim Biophys Acta 2014;1841:323-30
5. Jungersted JM, Scheer H, Mempel M, et al. Stratum corneum lipids, skin barrier function and filaggrin mutations in patients with atopic eczema. Allergy 2010;65:911-18
6. Holm EA, Wulf HC, Stegmann H, Jemec GB. Life quality assessment among patients with atopic eczema. Br J Dermatol 2006;154:719-25
7. Proudfoot LE, Powell AM, Ayis S, et al. The European TREatment of severe Atopic eczema in childrenTaskforce (TREAT) survey. Br J Dermatol 2013;169:901-9
8. Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol 2014;71(2):327-49
9. Work Group. Eichenfield LF, Tom WL, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopicdermatitis with topical therapies. J Am Acad Dermatol 2014;71(1):116-32
10. Arkwright PD, Motala C, Subramanian H, et al. Management of difficult-to-treat atopic dermatitis. J Allergy Clin Immunol Pract 2013;1:142-51
11. Jacobi A, Antoni C, Manger B, et al. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2005;52:522-6
12. Rullan P, Murase J. Two cases of chronic atopic dermatitis treated with soluble tumor necrosis factor receptor therapy. J Drugs Dermatol 2009;8:873-6
13. Yayli S, Irla N, Yawalkar N. Adalimumab in recalcitrant severe psoriasis associated with atopic dermatitis. Case Rep Dermatol 2013;5:332-5
14. Ruiz-Villaverde R, Galán-Gutierrez M. Exacerbation of atopic dermatitis in a patient treated with infliximab. Actas Dermosifiliogr 2012;103:743-6
15. Vestergaard C, Deleuran M, Kragballe K. Two cases of atopic dermatitis-like conditions induced in psoriasis patients treated with infliximab. J Eur Acad Dermatol Venereol 2007;21:1272-4
16. Puya R, Alvarez-Lopez M, Velez A, et al. Treatment of severe refractory adult atopic dermatitis with ustekinumab. Int J Dermatol 2012;51:115-16
17. Agusti-Mejias A, Messeguer F, Garca R, Febrer I. Severe refractory atopic dermatitis in an adolescent patient successfully treated with ustekinumab. Ann Dermatol 2013;25:368-70
18. Fernández-Anton Martnez MC, Alfageme Roldán F, Ciudad Blanco C, Suárez Fernández R. Ustekinumab in the treatment of severe atopic dermatitis: a preliminary report of our experience with 4 patients. Actas Dermosifiliogr 2014;105:312-13
19. Kikly K, Liu L, Na S, Sedgwick JD. The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation. Curr Opin Immunol 2006;18:670-5
20. Steward-Tharp SM, Song YJ, Siegel RM, OShea JJ. New insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppression. Ann N Y Acad Sci 2010;1183:123-48
21. Simon D, Aeberhard C, Erdemoglu Y, Simon HU. Th17 cells and tissue remodeling in atopic and contact dermatitis. Allergy 2014;69:125-31
22. Wang SS, Hon KL, Kong AP, et al. Vitamin D deficiency is associated with diagnosis and severity of childhood atopic dermatitis. Pediatr Allergy Immunol 2014;25(1):30-5
23. Hotze M, Baurecht H, Rodrguez E, et al. Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines. Allergy 2014;69:132-5
24. Kim DH, Park KY, Kim BJ, et al. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol 2013;38:496-500
25. Fernández-Anton Martnez MC, Leis-Dosil V, Alfageme-Roldán F, et al. Omalizumab for the treatment of atopic dermatitis. Actas Dermosifiliogr 2012;103:624-8
26. Heil PM, Maurer D, Klein B, et al. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges 2010;8:990-8
27. Lyengar SR, Hoyte EG, Loza A, et al. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebocontrolled clinical trial. Int Arch Allergy Immunol 2013;162:89-93
28. Sánchez-Ramon S, Eguluz-Gracia I, Rodrguez-Mazariego ME, et al. Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis. J Investig Allergol Clin Immunol 2013;23:190-6
29. Moul DK, Routhouska SB, Robinson MR, Korman NJ. Alefacept for moderate to severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 2008;58:984-9
30. Simon D, Bieber T. Systemic therapy for atopic dermatitis. Allergy 2014;69:46-55
31. Ibler K, Dam TN, Gniadecki R, et al. Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases. J Eur Acad Dermatol Venereol 2010;24:837-9
32. Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010;47:115-23
33. Worm M, Henz BM. Molecular regulation of human IgE synthesis. J Mol Med (Berl) 1997;75:440-7
34. Simon D, Hosli S, Kostylina G, et al. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008;121:122-8
35. Arend WP. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest 1991;88:1445-51
36. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013;368:2455-66
37. Grimstad O, Sawanobori Y, Vestergaard C, et al. Anti-interleukin-31- antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis. Exp Dermatol 2009;18:35-43
38. Schett G, Sloan VS, Stevens RM, Schafer P. Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases. Ther Adv Musculoskelet Dis 2010;2:271-8
39. Grewe SR, Chan SC, Hanifin JM. Elevated leukocyte cyclic AMPphosphodiesterase in atopic disease: a possible mechanism for cyclic AMPagonist hyporesponsiveness. J Allergy Clin Immunol 1982;70:452-7
40. Hanifin JM, Lloyd R, Okubo K, et al. Relationship between increased cyclic AMP-phosphodiesterase activity and abnormal adenylyl cyclase regulation in leukocytes from patients with atopic dermatitis. J Invest Dermatol 1992;98(6 Suppl):100S-5S
41. Samrao A, Berry TM, Goreshi R, Simpson EL. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol 2012;148:890-7
42. Volf EM, Au SC, Dumont N, et al. A phase 2, open-label, investigatorinitiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis. J Drugs Dermatol 2012;11:341-6
43. Townley RG, Agrawal S. CRTH2 antagonists in the treatment of allergic responses involving TH2 cells, basophils, and eosinophils. Ann Allergy Asthma Immunol 2012;109:365-74
44. Franciosi LG, Diamant Z, Banner KH, et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med 2013;1:714-27
45. Shiraishi Y, Takeda K, Domenico J, Gelfand EW. Role of prostaglandin D(2) and CRTH2 blockade in early- and latephase nasal responses. Clin Exp Allergy 2014;44(8):1076-82
46. Yahara H, Satoh T, Miyagishi C, Yokozeki H. Increased expression of CRTH2 on eosinophils in allergic skin diseases. J Eur Acad Dermatol Venereol 2010;24:75-6
47. Raap U, Ständer S, Metz M. Pathophysiology of itch and new treatments. Curr Opin Allergy Clin Immunol 2011;11:420-7
48. Ständer S, Siepmann D, Herrgott I, et al. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One 2010;5(6):e10968
49. Ohmura T, Hayashi T, Satoh Y, et al. Involvement of substance P in scratching behaviour in an atopic dermatitis model. Eur J Pharmacol 2004;491:191-4
50. Salomon J, Baran E. The role of selected neuropeptides in pathogenesis of atopic dermatitis. J Eur Acad Dermatol Venereol 2008;22:223-8
51. Bak H, Lee WJ, Lee YW, et al. Expression of neuropeptides and their degrading enzymes in ACD. Clin Exp Dermatol 2010;35:318-23
52. Mao XQ, Shirakawa T, Yoshikawa T, et al. Association between genetic variants of mast-cell chymase and eczema. Lancet 1996;348(9027):581-3
53. Tanaka K, Sugiura H, Uehara M, et al. Association between mast cell chymase genotype and atopic eczema: comparison between patients with atopic eczema alone and those with atopic eczema and atopic respiratory disease. Clin Exp Allergy 1999;29:800-3
54. Weidinger S, Rummler L, Klopp N, et al. Association study of mast cell chymase polymorphisms with atopy. Allergy 2005;60:1256-61
55. Terakawa M, Fujieda Y, Tomimori Y, et al. Oral chymase inhibitor SUN13834 ameliorates skin inflammation as well as pruritus in mouse model for atopic dermatitis. Eur J Pharmacol 2008;601:186-91
56. Bissonnette R, Chen G, Bolduc C, et al. Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: results from a phase 2A, randomized, placebo-controlled clinical trial. Arch Dermatol 2010;146:446-9
57. Bissonnette R, Poulin Y, Zhou Y, et al. Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebocontrolled double-blind trial. Br J Dermatol 2012;166:853-60
58. Wiren K, Nohlgard C, Nyberg F, et al. Treatment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial. J Eur Acad Dermatol Venereol 2009;23:1267-72
59. Ryan C, Shaw RE, Cockerell CJ, et al. Novel sodium hypochlorite cleanser shows clinical response and excellent acceptability in the treatment of atopic dermatitis. Pediatr Dermatol 2013;30:308-15
60. Bostoen J, Bracke S, De Keyser S, Lambert J. An educational programme for patients with psoriasis and atopic dermatitis: a prospective randomized controlled trial. Br J Dermatol 2012;167:1025-31
61. Simpson E, Bohling A, Bielfeldt S, et al. Improvement of skin barrier function in atopic dermatitis patients with a new moisturizer containing a ceramide precursor. J Dermatolog Treat 2013;24:122-5
62. Na JI, Hwang JS, Park HJ, et al. A new moisturizer containing physiologic lipid granules alleviates atopic dermatitis. J Dermatolog Treat 2010;21:23-7
63. Miller DW, Koch SB, Yentzer BA, et al. An over-the-counter moisturizer is as clinically effective as, and more costeffective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial. J Drugs Dermatol 2011;10:531-7